

Technology Advisory Committee B Interests Register

Dupilumab for treating prurigo nodularis [ID4054]

Publication Date: 13/12/2023

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Ser Ling Chua	Clinical Expert	Indirect Conflict - None	<p>Of the work below is related to prurigo nodularis or dupilumab</p> <p>Novartis – honoraria or consultation fees (May 2022) and funding of attendance at education activities (Sep 2022)</p> <p>Almirall - funding of attendance at education activities (Nov 2022)</p> <p>Boehringer Ingelheim – honoraria or consultation fees (March 2022)</p>	25/11/2022	N/A	It was agreed that Ser Ling Chua's declaration would not prevent [him/her] from providing expert advice to the committee.